OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing next-generation therapies for vision-threatening eye diseases, led by its bispecific antibody OLN324 for DME and wet AMD.
2 Pulse stories
TB
Triveni BioClinical-stage biotech developing genetics-informed antibody therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
$430M
$272M
Ollin BiosciencesTriveni Bio
Last ValuationNot disclosed
Biotech
Sector
Biotech
2023
Founded
2023
Chicago, Illinois
HQ
Watertown, Massachusetts
Private
Status
Private
Ollin Biosciences investors
ARCH Venture PartnersTCGXa16z Bio+HealthMubadala CapitalPolaris PartnersRA Capital ManagementCPP InvestmentsBlackstone Multi-Asset Investing
Triveni Bio investors
Ascenta CapitalJanus Henderson InvestorsDeep Track Capital
Data from Value Add Pulse coverage and company research — see the full threads for Ollin Biosciences and Triveni Bio.